企業プロフィール
InMed 株価・ニュース・カタリスト
- ティッカー:
- INM
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- Canada and listed in the U
株価パフォーマンス
1.35 USD (-0.74%)
終値
最終更新: 2026年10月1日
5.04M USD
時価総額
株価変動の要因
2026年10月1日 時点で INM は 0.74% 下落し、$1.35 で取引を終えました。現在のニュース監視期間内に同社の新しいニュースは確認されませんでした。
企業概要
Small-Molecule Drug Portfolio Company
InMed Pharmaceuticals has developed cannabinoid-related and other small-molecule candidates for neurological, ophthalmic, and dermatologic diseases. The company is seeking strategic transactions for its legacy development programs.
INM-901 for Alzheimer's Disease
INM-901 is a small-molecule candidate being explored for Alzheimer's disease. Preclinical work has evaluated potential effects on neuroinflammation, neuronal function, and disease-related pathology.
INM-089 for Dry AMD
INM-089 is being developed for dry age-related macular degeneration. The program is intended to address retinal degeneration through a differentiated small-molecule mechanism.
INM-755 Dermatology Program
INM-755 is a topical candidate that has been studied in dermatologic conditions, including symptoms associated with epidermolysis bullosa. It remains part of the portfolio available for licensing or other strategic development.
Transition from BayMedica
InMed discontinued operations at BayMedica, its rare-cannabinoid manufacturing subsidiary. The remaining strategy emphasizes monetization, licensing, or transfer of the pharmaceutical assets rather than maintaining a vertically integrated commercial cannabinoid business.
今後のカタリスト
最近のニュース
ニュースタイトルは機械翻訳です。詳細は英語の原文をご覧ください。
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。